Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Opko Health, Accuray, Medicines, DaVita, and DENTSPLY Intl. Early Briefing and Review

April 15, 2013

LONDON, April 15, 2013 /PRNewswire/ –

One of the most controversial features of the Affordable Care Act (ACA) has been the
2.3% tax on total sales of taxable medical devices by medical equipment & supplies
companies. The controversial tax will lead to higher costs for medical devices companies
such as Accuray Incorporated (NASDAQ: ARAY) and DENTSPLY International Inc. (NASDAQ:
XRAY). On March 21, however, the Senate voted 79 to 20 to pass a non-binding budget
amendment, which encourages the repeal of the medical device excise tax. The ACA is also
expected to have a significant impact on other players in the healthcare industry,
including Opko Health Inc. (NYSE: OPK), The Medicines Company (NASDAQ: MDCO), and DaVita
Healthcare Partners Inc. (NYSE: DVA). Healthcare stocks ended mostly lower on Friday,
tracking losses in the broad market, which struggled following the release of some
disappointing economic data. StockCall has released free charting and technical research
on these aforementioned companies. Register to read these reports at

http://www.stockcall.com/report

Shares of Opko Health Inc. ended marginally lower in Friday’s trading session. The
stock closed 0.28% lower at $7.17 on volume of 807,625. Despite the pullback last Friday,
Opko’s shares have gained more than 3.10% in the last three sessions. The company’s shares
are currently trading close to their 52-week high of $7.22. The stock has had an excellent
run so far in 2013, gaining more than 49%. Sign up for the free report on OPK at

http://www.StockCall.com/OPK041513.pdf

Shares of Accuray Incorporated fluctuated between gains and losses on Friday before
finishing the day flat at $4.81. Despite struggling for direction last Friday, shares of
ARAY have gained nearly 3.90% in the last three trading sessions. The stock recently
crossed above its 50-day moving average, which is a bullish signal. The positive trend is
further confirmed by its MACD chart. ARAY free technical report can be accessed by signing
up at

http://www.StockCall.com/ARAY041513.pdf

Shares of The Medicines Company’s shares posted modest gains in Friday’s session. The
stock closed 0.21% higher at $32.82 on volume of 408,552. The company shares have gained
3.40% in the last three trading sessions, which indicates that market sentiment is
currently bullish on the stock. It is currently trading 6.73% below its 52-week high.
Year-to-date, shares of MDCO have gained nearly 37%, outperforming the S&P 500. Free
report on MDCO can be accessed by registering at

http://www.StockCall.com/MDCO041513.pdf

Shares of DaVita Healthcare Partners Inc. edged lower on Friday; however, the losses
were limited. The stock closed 0.11% lower at $126.91 on volume of 447,300. The company’s
shares have outperformed the S&P 500 so far in 2013, gaining more than 14.80%, compared to
a gain of more than 11.40% for the S&P 500. DaVita’s shares are currently trading well
above its 50-day and 200-day moving averages, which is a bullish signal. Register with
StockCall and download the research on DVA for free at

http://www.StockCall.com/DVA041513.pdf

Shares of DENTSPLY International Inc. edged lower in Friday’s trading session. The
stock fell to an intra-day low of $41.89 before paring some of the losses to finish the
day 0.43% lower at $42.04 on above average volume of 680,800. Despite the decline last
Friday, DENTSPLY’s shares have gained nearly 1.80% in the last three sessions. The stock
is currently struggling to break through $42.50 resistance level. It has support at around
$41.50. Read the full free research on XRAY by signing up to StockCall at

http://www.StockCall.com/XRAY041513.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and
comprehensive research and opinions on stocks making the headlines. Sign up today to talk
to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com


Source: PR Newswire